FDA approves daraxonrasib pill for advanced pancreatic cancer, clearing new once-daily option

The Food and Drug Administration approved daraxonrasib, a new oral treatment for advanced pancreatic cancer, clearing a once-daily pill for patients who have already tried earlier options, The Hill reported on Wednesday. According to the report, the drug, developed by Revolution Medicines, will be sold under the brand name Rasonque. The approval is for a setting involving advanced pancreatic cancer and is described as providing new life-extending care for patients with one of the most aggressive forms of cancer, The Hill said. The Hill reported that daraxonrasib is administered as a once-daily pill rather than an infusion-based therapy, a practical change that can affect how care is delivered in oncology settings and how patients and clinicians schedule treatment around visits and other daily needs. The report states that the FDA’s approval is for patients who already tried prior treatment, but it does not detail in the provided packet which specific prior therapies were included in the approval criteria. The precise patient-eligibility language, dosing, and whether the approval covers particular tumor markers or line-of-therapy thresholds were not included in the supplied material. The FDA approval also raises questions about next-step access and implementation, including how quickly prescriptions are expected to reach oncology practices, how payers will set coverage terms, and what additional data clinicians will look for to determine how daraxonrasib fits into existing treatment sequencing for advanced pancreatic cancer. Revolution Medicines’ role in developing the therapy, and the FDA’s decision to approve the regimen, mark a new addition to the limited menu of treatments for advanced pancreatic cancer, The Hill said. As with other FDA approvals, post-marketing monitoring and updates to prescribing information typically follow, though details were not provided in the supplied record.